Epigenetics, the study of heritable changes in gene expression without changes to the DNA sequence, has emerged as an important regulator of disease risk and development. Epigenetic alterations, such as DNA methylation, histone modifications, and non-coding RNAs, act as molecular bridges between genetic predisposition and environmental factors. Understanding these changes is critical for determining the pathophysiology of chronic illnesses. This article looks at the involvement of epigenetic mechanisms in chronic diseases such as cardiovascular disease, obesity, depression, Alzheimer's disease, and diabetes mellitus. The emphasis is on recent epigenetic discoveries, their implications for disease risk assessment, and the prospect of epigenetic-based therapeutics in precision medicine. Epigenome-Wide Association Studies (EWAS) and next-generation sequencing technologies have revealed disease-specific epigenetic patterns, underlining their potential as biomarkers for early detection and risk stratification. Epigenetic changes affect important molecular pathways that control metabolic regulation, neuroplasticity, inflammatory response, and cellular homeostasis. Epigenetic modification-targeting therapies, such as DNA methylation inhibitors, histone deacetylase inhibitors, and RNA-based treatments, have shown promise in preclinical and early clinical trials. Epigenetic research offers a transformational framework for understanding the intricate interplay of genetic and environmental variables in chronic illness etiology. Epigenetic alterations are reversible, which opens up new possibilities for therapeutic intervention and individualized therapy. Future research should concentrate on improving epigenetic biomarkers, determining causal links in disease progression, and incorporating epigenetic findings into clinical practice. The advancement of epigenetic medicines has the potential to transform disease prevention, treatment, and global health policies.
Aldahish et al. (Fri,) studied this question.